Chemically Modified TPO mRNA Stimulates Thrombopoiesis in Mice

Study Background and Research Question

Messenger RNA (mRNA) therapeutics have rapidly advanced from proof-of-concept to clinical reality, exemplified by the success of mRNA vaccines. Beyond infectious disease, the potential for mRNA-based interventions to treat hematological disorders is a major area of investigation. Thrombopoietin (TPO) is the primary physiological regulator of platelet production via stimulation of megakaryocyte differentiation. Recombinant TPO protein and TPO receptor agonists have previously shown efficacy in increasing platelet counts but present risks, such as immunogenicity and thrombocytosis, prompting the search for safer alternatives. The reference study (Zhang et al., 2022) addresses whether chemically modified, in vitro-transcribed TPO mRNA can safely and effectively stimulate thrombopoiesis in vivo, potentially offering a new therapeutic avenue for thrombocytopenia.

Key Innovation from the Reference Study

The core innovation lies in the synthesis and in vivo application of N1-methylpseudouridine (m1Ψ)-modified TPO mRNA. Unlike prior recombinant protein therapies, this approach leverages mRNA’s transient expression profile and the ability to fine-tune translation kinetics, reducing risks of persistent overexpression or immune responses. The study demonstrates successful delivery of the modified mRNA encapsulated in lipid nanoparticles, resulting in robust, dose-dependent protein production and functional hematological outcomes in mice. This work illustrates the promise of mRNA-based protein replacement for hematopoietic support, with direct implications for immune-mediated and chemotherapy-induced thrombocytopenia.

Methods and Experimental Design Insights

To generate functional TPO mRNA, the researchers employed in vitro transcription using a T7 RNA polymerase system, incorporating N1-methylpseudouridine to enhance stability and reduce innate immune sensing. Post-transcriptional modification included enzymatic capping and polyadenylation to mimic endogenous mRNA structure, which is critical for stability and translation efficiency. Purified mRNA was encapsulated in lipid nanoparticles (LNPs) for systemic delivery.

In vivo, C57BL/6 mice received a single intravenous injection of TPO mRNA-loaded LNPs at various doses. Plasma TPO protein levels and platelet counts were measured at multiple timepoints. The functional impact was further assessed in a model of antibody-induced thrombocytopenia—testing the ability of the mRNA therapy to accelerate platelet recovery following immune-mediated depletion.

Protocol Parameters

• In vitro transcription: Incorporate N1-methylpseudouridine triphosphate in place of uridine for reduced immunogenicity and improved mRNA stability.
• Cap and tail structure: Employ co-transcriptional or enzymatic capping (Cap 1 structure) and post-transcriptional polyadenylation to achieve a poly (A) tail length of ≥150 nucleotides.
• LNP formulation: Encapsulate purified mRNA using established lipid nanoparticle protocols for intravenous delivery.
• Dosing regimen: Single intravenous administration; evaluate plasma TPO and platelet counts at 2, 6, 24, and 72 hours post-injection.
• Thrombocytopenia modeling: Induce acute thrombocytopenia in mice using anti-GPIbα (CD42b) antibody; assess recovery following mRNA or comparator treatment.

Core Findings and Why They Matter

Administration of chemically modified TPO mRNA in mice led to a dramatic increase in plasma TPO protein—exceeding baseline levels by over 1,000-fold in a dose-dependent manner, as reported in the reference study. This translated to significant increases in both reticulated and total platelet counts, confirming the biological activity of the translated TPO. Notably, even submicrogram doses of mRNA yielded effects comparable to those of the approved TPO receptor agonist romiplostim, highlighting the efficiency of mRNA-mediated protein expression.

In the immune thrombocytopenia model, TPO mRNA treatment facilitated rapid platelet recovery, demonstrating potential for therapeutic application. The rapid onset and transient nature of mRNA-driven protein expression offer potential safety advantages over persistent protein or small-molecule agonist therapies.

Comparison with Existing Internal Articles

Internal resources such as "Reliable Polyadenylation with HyperScribe™ Poly (A) Tailing Kit" and "Precision RNA Polyadenylation for Advanced Molecular Research" emphasize the importance of robust, reproducible polyadenylation for mRNA stability enhancement and translation efficiency improvement. The reference study's workflow, incorporating enzymatic poly (A) tailing and capping, aligns with the optimized protocols detailed in these internal articles, which highlight the utility of E. coli Poly (A) Polymerase for achieving reliable in vitro transcription RNA modification. These best practices are mirrored in the reference work’s methodology, underscoring the critical nature of post-transcriptional mRNA processing in successful therapeutic applications.

Articles such as "Solving Lab mRNA Stability and Translation Challenges" further contextualize the impact of high-quality polyadenylation on downstream transfection experiments, a key step in the reference study’s in vivo delivery strategy. Collectively, these resources reinforce the translational value of precise, enzyme-based mRNA processing protocols.

Limitations and Transferability

While the results in murine models are compelling, several limitations remain. The study was conducted exclusively in mice, and translation to human systems will require careful consideration of immunogenicity, pharmacokinetics, and optimal dosing regimens. The safety of repeated dosing, potential for unintended immune activation, and long-term effects were not addressed in this initial work. Furthermore, while the mRNA construct was highly effective at stimulating thrombopoiesis, broader applicability to other cytokines or therapeutic proteins will require additional validation.

Transferability to clinical settings hinges on the scalability and reproducibility of mRNA synthesis and LNP formulation, as well as regulatory considerations unique to mRNA-based therapeutics. Nonetheless, the study provides a strong foundation for further translational research in mRNA-mediated protein replacement therapies.

Research Support Resources

For researchers seeking to replicate or build upon the mRNA synthesis and modification strategies described in this study, enzymatic polyadenylation is a critical step. The HyperScribe™ Poly (A) Tailing Kit (SKU K1053) from APExBIO provides a convenient, enzyme-based solution utilizing E. coli Poly (A) Polymerase for generating polyadenylated RNA transcripts suitable for in vitro transcription RNA modification workflows. Employing such optimized kits can help ensure mRNA stability and translation efficiency, supporting robust outcomes in transfection and gene expression studies that parallel the approaches used in the reference investigation.